Table 2.
Baseline characteristics and Functional Assessment of Cancer Therapy-Lung (FACT-L) scores of both groups.
| Characteristic | Mobile application arm (n = 17) | Routine follow-up arm (n = 16) | p-value |
|---|---|---|---|
| Sex, No. (%) | |||
| Male | 9 (53) | 12 (75) | |
| Female | 8 (47) | 4 (25) | |
| Median age (SD), years-old | 61.6 (10.5) | 63.8 (12.7) | |
| Performance status, No. (%) | 0.99 | ||
| 0 | 1 (5.9) | 1 (6.25) | |
| 1 | 9 (52.9) | 8 (50) | |
| 2 | 4 (23.5) | 4 (25) | |
| 3 | 2 (11.8) | 2 (12.5) | |
| 4 | 1 (5.9) | 1 (6.25) | |
| Histology subtype, No. (%) | 0.29 | ||
| Adenocarcinoma | 17 (100) | 15 (93.75) | |
| Small cell lung cancer | 0 | 1 (6.25) | |
| Technical skill, No. (%) | 0.86 | ||
| Able | 9 (53) | 8 (50) | |
| Family aids | 8 (47) | 8 (50) | |
| Active treatment, No. (%) | 0.32 | ||
| Chemotherapy | 9 (52.9) | 12 (75) | |
| Targeted therapy | 7 (41.2) | 4 (25) | |
| Immunotherapy | 1 (5.9) | 0 | |
| Line of treatment, No. (%) | 0.92 | ||
| 1st line | 13 (76.5) | 12 (75) | |
| 2nd line | 4 (23.5) | 4 (25) | |
| Symptom scores by application at baseline, mean (lower 95% mean, upper 95% mean, SE) | 6.88 (4.78, 8.97, SE = 0.98) | 7.25 (4.78, 9.38, SE = 1.01) | 0.79 |
| FACT-L at baseline, mean (lower 95% mean, upper 95% mean, SE) | 90 (79.1, 101.1, SE = 5.4) | 91.8 (80.4, 103.1, SE = 5.6) | 0.82 |
| FACT-L after 3 months (mean, lower 95% mean, upper 95% mean, SE) | 99.96 (88.0, 111.85, SE = 5.74) | 106.0 (93.63, 118.37, SE = 5.97) | 0.07 |
| Difference in FACT-L score between baseline and 3 months follow-up | 8.18 ± 0.34 (missing = 7) | 15.92 ± 0.37 (missing = 7) | 0.05* |
* = means comparisons for all pairs using Tukey-Kramer HSD.